Resonance Health Ltd

Healthcare AU RHT


Last update at 2024-05-29T02:06:00Z

Day Range


52 Week Range



Income Statement


Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Income before tax -1.26406M -1.55152M 0.34M -0.95270M 0.94M
Minority interest - - - - -
Net income -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Selling general administrative 3.14M 2.50M 2.00M 3.57M 1.67M
Selling and marketing expenses 0.82M 1.02M 0.24M 0.24M 0.27M
Gross profit 4.40M 3.83M 3.78M 3.67M 3.62M
Reconciled depreciation 0.44M 0.43M 0.36M 0.34M 0.25M
Ebit -1.59339M -1.77245M 0.19M -1.17992M 0.87M
Ebitda -1.15703M -1.34334M 0.55M -0.83934M 1.11M
Depreciation and amortization 0.44M 0.43M 0.36M 0.34M 0.25M
Non operating income net other - - - - -
Operating income -1.59339M -1.77245M 0.19M -1.17992M 0.87M
Other operating expenses 6.03M 5.60M 3.59M 4.85M 2.76M
Interest expense - 0.00332M 0.16M 0.23M 0.07M
Tax provision -0.48370M -0.40975M -0.24233M -0.23762M -0.32856M
Interest income 0.29M 0.00332M 0.09M 0.00402M 0.04M
Net interest income 0.04M 0.00332M 0.04M 0.04M 0.04M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -0.48369M -0.40975M -0.24233M -0.23762M -0.32855M
Total revenue 4.40M 3.83M 3.78M 3.67M 3.62M
Total operating expenses 6.03M 5.60M 3.59M 4.85M 2.76M
Cost of revenue - - - - -
Total other income expense net 0.32M 0.22M 0.16M 0.23M 0.07M
Discontinued operations - - - - -
Net income from continuing ops -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Net income applicable to common shares -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Preferred stock and other adjustments - - - - -
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Total assets 10.98M 11.69M 12.44M 10.50M 6.42M
Intangible assets 2.71M 2.87M 2.59M 2.53M 2.55M
Earning assets - - - - -
Other current assets - 0.06M 0.04M 0.04M 0.04M
Total liab 1.05M 1.00M 0.61M 0.59M 0.52M
Total stockholder equity 9.94M 10.69M 11.83M 9.91M 5.89M
Deferred long term liab 2.71M 2.87M 2.59M 2.53M 2.55M
Other current liab 0.01M 0.46M 0.40M 0.41M 0.38M
Common stock 73.88M 73.88M 73.88M 72.57M 69.67M
Capital stock 73.88M 73.88M 73.88M 72.57M 69.67M
Retained earnings -66.04170M -65.26134M -64.11956M -64.70542M -63.99035M
Other liab - - - - -
Good will - - - - -
Other assets 2.80M 2.95M 2.64M 2.58M 2.60M
Cash 6.36M 6.78M 8.86M 6.97M 3.08M
Cash and equivalents 1.04M 6.78M 6.09M 6.97M 3.08M
Total current liabilities 0.88M 0.81M 0.61M 0.53M 0.52M
Current deferred revenue 0.62M 0.02M 0.03M 0.01M 0.05M
Net debt -6.08868M -6.51495M -8.79672M -6.85813M -3.08119M
Short term debt 0.10M 0.08M 0.06M 0.06M 0.00000M
Short long term debt - - - - -
Short long term debt total 0.27M 0.27M 0.06M 0.12M -
Other stockholder equity -0.27058M 2.07M 2.06M 2.05M 0.21M
Property plant equipment 0.63M 0.39M 0.11M 0.14M 0.04M
Total current assets 7.56M 8.35M 9.69M 7.78M 3.78M
Long term investments 0.08M 0.08M 0.05M 0.05M 0.05M
Net tangible assets 9.94M 10.69M 11.83M 9.91M 5.89M
Short term investments - - - - -
Net receivables 1.14M 1.51M 0.79M 0.77M 0.66M
Long term debt - - - - -
Inventory - - - - -
Accounts payable 0.15M 0.24M 0.12M 0.05M 0.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 2.09M 2.07M 2.06M 2.05M 0.21M
Additional paid in capital - - - - -
Common stock total equity - - - 72.57M 69.67M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 0.08M 0.08M 0.05M 0.05M 0.05M
Deferred long term asset charges - - - - -
Non current assets total 3.43M 3.34M 2.75M 2.72M 2.64M
Capital lease obligations 0.27M 0.27M 0.06M 0.12M -
Long term debt total 0.17M 0.19M 0.00000M 0.06M 0.00000M
Breakdown 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Type yearly yearly yearly yearly yearly
Date 2023-06-30 2022-06-30 2021-06-30 2020-06-30 2019-06-30
Investments -0.46790M -0.70400M -0.39579M -0.25063M -0.34799M
Change to liabilities 0.04M 0.20M 0.11M -0.04408M -0.05059M
Total cashflows from investing activities -0.46790M -0.70400M -0.39579M -0.25063M -0.34799M
Net borrowings -0.08197M -0.07013M -0.05189M -0.05167M -0.05167M
Total cash from financing activities -0.08197M -0.10712M 1.20M 2.82M 0.25M
Change to operating activities 0.02M -0.04559M -0.03368M -0.00359M 0.01M
Net income -0.78036M -1.14178M 0.59M -0.71508M 1.27M
Change in cash -0.42154M -2.07365M 1.88M 3.89M 1.53M
Begin period cash flow 6.78M 8.86M 6.97M 3.08M 1.55M
End period cash flow 6.36M 6.78M 8.86M 6.97M 3.08M
Total cash from operating activities -0.15703M -0.71267M 1.17M 1.31M 1.62M
Issuance of capital stock - - 1.25M 2.89M 0.25M
Depreciation 0.44M 0.43M 0.36M 0.34M 0.25M
Other cashflows from investing activities - - - - -
Dividends paid - - - - -
Change to inventory - - - - -
Change to account receivables 0.36M -0.71466M -0.02477M -0.10328M -0.10332M
Sale purchase of stock - 0.00000M 1.25M -0.01500M 0.25M
Other cashflows from financing activities -0.08197M -0.10712M -0.05189M -0.05167M 0.25M
Change to netincome -0.22947M -0.18699M 0.17M 1.84M 0.24M
Capital expenditures 0.47M 0.70M 0.40M 0.25M 0.35M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital 0.42M -0.55549M 0.05M -0.15094M -0.13934M
Stock based compensation 0.02M 0.00562M 0.03M 1.85M 0.24M
Other non cash items -0.22947M 0.56M 0.17M 1.84M 0.24M
Free cash flow -0.62493M -1.41667M 0.77M 1.06M 1.27M


  • Previous Close 0.07
  • Market Cap28.59M
  • Volume191187
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-1.11924M
  • Revenue TTM5.64M
  • Revenue Per Share TTM0.01
  • Gross Profit TTM 4.47M
  • Diluted EPS TTM-

Peer Comparison

Sector: Healthcare Industry: Health Information Services

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
Resonance Health Ltd
-0.005 7.69% 0.06 - - 6.34 3.63 5.42 -29.9271
Pro Medicus Ltd
1.45 1.28% 114.69 172.97 113.64 78.98 70.50 78.09 106.71
Medadvisor Ltd
0.01 2.33% 0.44 - 25.97 1.29 2.56 1.22 -108.7944
Oneview Healthcare PLC
-0.015 4.92% 0.29 - - 26.22 16.80 25.10 -29.9289
CogState Ltd
-0.02 1.60% 1.23 24.60 32.79 5.22 3.67 4.24 22.21

Reports Covered

Stock Research & News


Resonance Health Limited, a healthcare technology and services company, designs, develops, manufactures, and commercializes software-as-medical devices in the Asia Pacific, North America, Europe, the Middle East, and Africa. The company offers FerriScan, a non-invasive MRI based system for quantifying liver iron concentration (LIC); FerriSmart, an artificial intelligence (AI) assisted device for the automated real-time assessment of LIC; HepaFat-AI, an AI-trained device for the automated real-time multi-metric measurement of liver-fat; CardiacT2, a dual analysis service with FerriScan for assessing heart iron loading; HepaFat-Scan, a non-invasive MRI-based solution for the assessment of liver-fat in liver tissue; and LiverSmart, a non-invasive MRI-based multi-parametric device combining FerriSmart and HepaFat-AI into a consolidated report. It also provides quantitative imaging measurements and CRO services, such as quality-assured image analysis, project and data management, and issue resolution services; biomarkers, genomics, and laboratory analysis services, as well as works with third party pathology laboratories for blood/sample collection and for standard biochemical/lab safety assessments; design and protocol development, and project management and monitoring services; assessment of subject inclusion or exclusion, evaluating the safety profile of a new therapy, and supporting primary and secondary end-points demonstrating drug efficacy services; and phantoms for the MRI machines. The company serves clinicians for the management of human diseases; and pharmaceutical and therapeutic companies for their clinical trials. Resonance Health Limited was incorporated in 1987 and is headquartered in Burswood, Australia.

Resonance Health Ltd

141 Burswood Road, Burswood, WA, Australia, 6100

Key Executives

Name Title Year Born
Mr. Mitchell M. Wells B.Com., B.Comm, L.L.B., LLB MD, Joint Company Sec. & Exec. Director 1975
Mr. Nicholas Allan A.C.A., B.Com. CFO, COO & Joint Company Sec. NA
Mr. Ben Winters Chief Technology Officer NA
Ms. Liesl Ellies Gen. Counsel & Joint Company Sec. NA
Mr. Chad Tondut Communications Mang. and GM of Products & Portfolio NA
Mr. Ajay Nair Gen. Mang. of Global Sales & Marketing NA
Dr. John Olynyk BMedSc, FRACP, M.D., MBBS Chief Medical Officer NA
Dr. Timothy Guy St. Pierre B.Sc(Hons), Ph.D. Chief Research Scientist NA
Dr. Wenjie Pang Ph.D. Chief Scientific Officer ? Imaging & AI NA
Dr. Sherif Boulos Ph.D. Chief Scientific Officer of Molecular NA

Disclaimer - Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peer trades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).